HA
ABBV icon

Hofer & Associates’s AbbVie ABBV Stock Holding History

Hofer & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$838K Buy
3,330
+105
+3% +$22.6K 0.41% 35
2026
Q1 		$701K Buy
3,225
+65
+2% +$14.4K 0.38% 34
2025
Q4 		$722K Buy
3,160
+25
+0.8% +$5.7K 0.38% 34
2025
Q3 		$726K Buy
+3,135
New +$638K 0.42% 33

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Hofer & Associates's ABBV Position: Q2 2026 in Review

Hofer & Associates increased its AbbVie (ABBV) stake by 3.3% in Q2 2026, buying an estimated $22.6K and bringing the position to 3,330 shares worth $838K. The position accounts for 0.41% of the portfolio, ranked #35.

Hofer & Associates first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 1,042 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hofer & Associates held 3,330 shares of AbbVie worth $838K as of Q2 2026.
  • Hofer & Associates bought 105 AbbVie shares in Q2 2026, an estimated $22.6K.
  • AbbVie made up 0.41% of Hofer & Associates's portfolio in Q2 2026, its #35 holding.
  • Hofer & Associates first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
  • 1,042 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hofer & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.